Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.

@article{Kostapanos2010RosuvastatinassociatedAE,
  title={Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.},
  author={Michael S. Kostapanos and Haralampos J. Milionis and Moses S Elisaf},
  journal={American journal of cardiovascular drugs : drugs, devices, and other interventions},
  year={2010},
  volume={10 1},
  pages={11-28}
}
HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern. Rosuvastatin has been proven to be efficacious in improving serum lipid profiles. Recently published data from the JUPITER study confirmed the efficacy of this statin in primary prevention for older patients with multiple risk factors and evidence of inflammation. Rosuvastatin exhibits high hydrophilicity and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
31 Citations
101 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 101 references

Similar Papers

Loading similar papers…